2017 Research Studies
- A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis.
- The purpose of this study is to determine whether the use of the study drug, secukinumab, can help treat patients who have non-radiographic ankylosing spondylitis. This study is currently actively enrolling. Further information is available at www.clinicaltrials.gov.
- Physicians and patients are welcome to contact us for more information.
- The principal investigator, Dr. Michael Bubb, can be reached at the rheumatology office, 352.294.8202.